Document is current

Article History

Accepted: 25 February 2024

First Online: 23 March 2024

Declarations

:

: This project has been funded, in part, by the European Union’s Horizon 2020 research and innovation programme under Grant agreement No. 825730.

: CH has received consulting fees from CSL Behring, Sobi, Novo Nordisk, and Uniqure. CH has received payment for lectures from CSL Behring, Sobi, and Novo Nordisk. All received payments were unrelated to this study. KG is employed by F. Hoffmann-La Roche AG. MP is employed by Novartis AG. This employment is unrelated to the study. NM, HF, and MS have declared no conflict of interest.

: Not applicable.

: Not applicable.

: Not applicable.

: All data generated or analysed during this study are included in this published article (and its supplementary information files) or are available from the corresponding author (NM) on reasonable request for non-commercial purposes.

: The model was implemented in R, and the full code is available from GitHub ().

: NM, MP, and MS conceived and designed the study. NM gathered the parameter inputs from the literature, implemented the model in R, and drafted the manuscript. CH contributed disease-area expertise and validated the clinical assumptions of the model in regard to haemophilia and its treatment strategies. KG contributed to the technical implementation and reviewed the R code during development of the model. HF, MP, and MS performed detailed reviews of the initial manuscript drafts. All authors were involved in the interpretation of the model results, reviewed the manuscript for important intellectual content, commented on it, and approved the final version.